The aim of this objective is to understand that In a new issue of Circulation, in the interest of the American Heart Association (AHA) Council on the Kidney in Cardiovascular Disease in organization with other AHA Councils, we and partners (7) have arranged a logical explanation on the cardiorenal defensive impacts of SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus and CKD. In a new issue of Circulation, for the American Heart Association (AHA) Council on the Kidney in Cardiovascular Disease in organization with other AHA Councils, we and partners (7) have arranged a logical articulation on the cardiorenal defensive impacts of SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus and CKD.
Reference link – https://journals.physiology.org/doi/full/10.1152/ajprenal.00518.2020
